Literature DB >> 1380359

Serum gastrin concentration in chronic renal failure.

P Kes1.   

Abstract

On the basis of the existing experimental and clinical studies about the factors affecting the appearance of hypergastrinemia in renal failure, it can be concluded that the kidney plays an important, but not the only, role in the degradation of endogenous gastrin in humans. In this process the key role is played by the blood flow through the kidney, the preservation of the peritubular capillary system, and the functional kidney mass. Glomerular filtration has no particular importance in the extraction of gastrin from the circulation, while through the urine only a small amount of gastrin is excreted. In the decomposition of a part or at least some molecular gastrin forms, an important role is played by the capillary systems of extra-renal tissue. One further conclusion is that hypergastrinemia in patients with renal failure is the result of the combined effects of the reduced catabolism of gastrin in the kidney and its increased synthesis which is for the most part connected with hypochlohydria and secondary hyperparathyroidism. In patients with renal failure there exists the inhibition of the gastrin acid secretion which is the cause of the weakening of the mechanism of the feedback connection between HCl and gastrin, while because of a permanent stimulation of G-cells, the hyperplasia of these cells develops, as well as the increased secretory activity, and hypergastrinemia. Parietal cells become less sensitive to a permanently increased serum gastrin concentration but still capable of reacting to the maximal stimulus. In patients with renal failure, especially those with extreme hypergastrinemia, there develops the increased concentration of large, mainly biologically inactive (big big gastrin, component I) molecular forms of gastrin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380359

Source DB:  PubMed          Journal:  Acta Med Croatica        ISSN: 1330-0164


  5 in total

1.  Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.

Authors:  Rabi Yacoub; Girish N Nadkarni; Daniel I McSkimming; Lee D Chaves; Sham Abyad; Mark A Bryniarski; Amanda M Honan; Shruthi A Thomas; Madan Gowda; John C He; Jaime Uribarri
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

2.  Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis.

Authors:  Lee D Chaves; Daniel I McSkimming; Mark A Bryniarski; Amanda M Honan; Sham Abyad; Shruthi A Thomas; Steven Wells; Michael Buck; Yijun Sun; Robert J Genco; Richard J Quigg; Rabi Yacoub
Journal:  Am J Physiol Renal Physiol       Date:  2018-04-25

3.  Black Spot, a Novel Gastric Finding Potentially Induced by Proton Pump Inhibitors.

Authors:  Yu Hatano; Ken Haruma; Maki Ayaki; Tomoari Kamada; Hiroshi Ohtani; Takahisa Murao; Noriaki Manabe; Hirohito Mori; Tsutomu Masaki; Akiko Shiotani
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

4.  Evaluation of screening tests for autoimmune gastritis in histopathologically confirmed Japanese patients, and re-evaluation of histopathological classification.

Authors:  Yasuhiro Wada; Shigemi Nakajima; Naoko Mori; Shizuki Takemura; Rena Chatani; Mariko Ohara; Makoto Fujii; Hiroshi Hasegawa; Kiyoyuki Hayafuji; Ryoji Kushima; Kazunari Murakami
Journal:  BMC Gastroenterol       Date:  2022-04-11       Impact factor: 3.067

5.  Gastric Hypersecretory States: Investigation and Management.

Authors:  Jennifer Phan; Jihane N Benhammou; Joseph R Pisegna
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.